← Back to patent-cliff list
CAS 1127-74-8
1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one
Codes: CONI-001
Application context (from source-drug indications)
HyponatraemiaConivaptan HydrochlorideAcute decompensated heart failureConivaptan HydrochlorideHeart failureConivaptan HydrochlorideLiver diseaseConivaptan HydrochlorideTraumatic brain injuryConivaptan HydrochlorideKidney diseaseConivaptan Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Conivaptan Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one→4-nitrobenzoyl chloride→1-(4-nitrobenzoyl)-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one→1-(4-aminobenzoyl)-1,2,3,4-tetrahydro-5H-benzo[b]azepin-5-one→[1,1'-biphenyl]-2-carboxylic acid→N-(4-(5-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-[1,1'-biphenyl]-2-carboxamide→acetimidamide hydrochloride→N-(4-(4-bromo-5-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-[1,1'-biphenyl]-2-carboxamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.